Just found something a little strange, slide 15.
In parallel, combination of DEP docetaxel and nintedanib (Vargatef) in lung cancer (4-12) patients.
I had beleived previously they indicated this combination arm to be planned for 12, and that they had completed it with a view to expanding it.
Therefore previously I had assumed 12 patients had already tested in the combination arm. After seeing this new slide with 4-12 patents i'm curious how many people have actually been included. Logically I would assume 4.
I'm not surprised now they wish to expand the combination study as 4 is very little.
